Tesamorelin stacks: what human studies actually tested

The tesamorelin trials discussed here studied tesamorelin against placebo. A separate experiment found a larger short-term growth hormone response with intravenous human GHRH and hexarelin together. Neither study compared tesamorelin plus ipamorelin with tesamorelin alone for visceral fat or safety.

Correction, November 10, 2026. The previous version misstated the US indication and inferred hormone and safety effects for specific combinations. This update links the prescribing information and separates the outcomes of the two human experiments.

What the label and the 26-week trial cover

The US EGRIFTA WR prescribing information covers reduction of excess abdominal fat in adults with HIV and lipodystrophy. The indication does not require prior failure of diet or exercise. The label specifies that the drug is not indicated for weight loss management.

In one randomized trial, 412 adults with HIV and abdominal fat accumulation received subcutaneous tesamorelin or placebo for 26 weeks. The reported change in CT-measured visceral adipose tissue was a 15.2% decrease with tesamorelin and a 5.0% increase with placebo. The trial compared tesamorelin with placebo in that population. ^[1]

What the hexarelin experiment measured

In 1996, Giustina and colleagues studied ten men with type 1 diabetes and seven controls. The participants received human GHRH, hexarelin, and the two together in separate intravenous tests. The combined test produced a larger acute growth hormone response than either agent alone. The authors described synergy in the controls and an additive response in the men with diabetes. The original abstract was read for this comparison. ^[2]

That experiment measured a hormone response to specific compounds given intravenously. It did not test tesamorelin, ipamorelin, or CJC-1295, or measure changes in visceral fat over weeks. A short-term growth hormone measurement cannot establish a longer-term body composition outcome.

What we can say about safety

The label warns about elevated IGF-1, fluid retention, glucose intolerance, hypersensitivity and reactions at the injection site. It describes the effects of prolonged IGF-1 elevations as unknown. Those warnings concern prescribed tesamorelin. The studies reviewed here do not quantify a combination’s effect on IGF-1, its long-term safety, or a change in cancer risk.

What would answer the stack question

A comparison of tesamorelin alone with the exact combination would need to measure the same clinical outcomes in both groups over a meaningful follow-up. Serial scans can describe change, but in an uncontrolled comparison other treatments, weight changes and the scan method can affect interpretation. The sources here leave the combination’s added benefit and risks unknown.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified clinician for individual medical decisions.